Ensysce Biosciences Inc
Company Profile
Business description
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Contact
7946 Ivanhoe Avenue
Suite 201
La JollaCA92037
USAT: +1 858 263-4196
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.30 | 6.80 | 0.08% |
| CAC 40 | 7,827.45 | 44.57 | -0.57% |
| DAX 40 | 23,666.81 | 55.48 | 0.23% |
| Dow JONES (US) | 46,121.28 | 171.50 | -0.37% |
| FTSE 100 | 9,250.43 | 27.11 | 0.29% |
| HKSE | 26,502.83 | 15.82 | -0.06% |
| NASDAQ | 22,497.86 | 75.62 | -0.33% |
| Nikkei 225 | 45,687.41 | 57.10 | 0.13% |
| NZX 50 Index | 13,064.15 | 117.16 | -0.89% |
| S&P 500 | 6,637.97 | 18.95 | -0.28% |
| S&P/ASX 200 | 8,749.00 | 11.10 | 0.13% |
| SSE Composite Index | 3,852.43 | 1.21 | -0.03% |